CRISPR Historical Balance Sheet

CRSP
 Stock
  

USD 78.70  1.24  1.60%   

Trend analysis of CRISPR Therapeutics AG balance sheet accounts such as Current Assets of 2.6 B, Assets Non Current of 360.8 M or Cash and Equivalents of 802.5 M provides information on CRISPR Therapeutics' total assets, liabilities, and equity, which is the actual value of CRISPR Therapeutics to its prevalent stockholders. By breaking down trends over time using CRISPR Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year. Financial Statement Analysis is much more than just reviewing and breaking down CRISPR Therapeutics prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CRISPR Therapeutics is a good buy for the upcoming year.
Continue to Trending Equities.
  

About CRISPR Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of CRISPR Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. CRISPR Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of CRISPR Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which CRISPR currently owns. An asset can also be divided into two categories, current and non-current.

CRISPR Therapeutics Balance Sheet Chart

CRISPR Therapeutics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how CRISPR Therapeutics uses and utilizes its capital. It also shows what exactly a company owns and owes.
CRISPR Therapeutics Shareholders Equity is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Shareholders Equity of 2.4 Billion. As of 12th of August 2022, Goodwill and Intangible Assets is likely to grow to about 128.3 K, while Accumulated Retained Earnings Deficit are likely to drop (211.4 M).

Total Assets

Total assets refers to the total amount of CRISPR Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in CRISPR Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; Investments; Goodwill and Intangible Assets; Property Plant and Equipment Net; [TaxAssets] and Trade and Non Trade Receivables.

Current Assets

Current assets of CRISPR Therapeutics AG include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of CRISPR Therapeutics. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Shareholders Equity

A principal component of the balance sheet; in addition to Total Liabilities and Total Assets; that represents the total of all stockholders' equity (deficit) items; net of receivables from officers; directors; owners; and affiliates of the entity which are attributable to the parent.

Total Liabilities

Deferred Income Tax is recorded on CRISPR Therapeutics AG balance sheet and a result of income already earned and recognized for accounting, but not tax, purposes. Also, differences between tax laws and accounting methods can result in a temporary difference in the amount of income tax payable by a company. This difference is recorded on CRISPR Therapeutics books as deferred income tax. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Principal components are Total Debt; Deferred Revenue; Trade and Non Trade Payables; Deposit Liabilities; and Tax Liabilities.
Most accounts from CRISPR Therapeutics balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into CRISPR Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.CRISPR Therapeutics Shareholders Equity is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Shareholders Equity of 2.4 Billion. As of 12th of August 2022, Goodwill and Intangible Assets is likely to grow to about 128.3 K, while Accumulated Retained Earnings Deficit are likely to drop (211.4 M).
 2019 2020 2021 2022 (projected)
Current Assets987.55 M1.72 B2.42 B2.61 B
Total Assets1.07 B1.83 B2.75 B2.97 B

CRISPR Therapeutics balance sheet Correlations

1.00.970.850.910.960.89-0.91.0-0.920.860.860.951.00.880.990.96-0.210.38
1.00.960.860.90.960.88-0.911.0-0.930.850.850.951.00.870.990.95-0.210.41
0.970.960.70.980.940.97-0.80.96-0.830.960.960.950.940.910.961.0-0.180.17
0.850.860.70.570.730.53-0.950.85-0.940.50.50.760.890.650.840.69-0.170.63
0.910.90.980.570.891.0-0.680.9-0.750.990.990.930.870.910.910.99-0.130.03
0.960.960.940.730.890.88-0.790.96-0.810.860.860.890.950.810.920.93-0.230.46
0.890.880.970.531.00.88-0.650.88-0.710.990.990.910.850.890.890.98-0.15-0.01
-0.9-0.91-0.8-0.95-0.68-0.79-0.65-0.910.94-0.62-0.62-0.8-0.92-0.68-0.86-0.790.28-0.5
1.01.00.960.850.90.960.88-0.91-0.920.850.850.941.00.850.980.96-0.220.4
-0.92-0.93-0.83-0.94-0.75-0.81-0.710.94-0.92-0.68-0.68-0.89-0.94-0.82-0.93-0.820.09-0.44
0.860.850.960.50.990.860.99-0.620.85-0.681.00.880.820.870.860.96-0.16-0.05
0.860.850.960.50.990.860.99-0.620.85-0.681.00.880.820.870.860.96-0.16-0.05
0.950.950.950.760.930.890.91-0.80.94-0.890.880.880.940.980.970.95-0.060.21
1.01.00.940.890.870.950.85-0.921.0-0.940.820.820.940.850.980.93-0.20.45
0.880.870.910.650.910.810.89-0.680.85-0.820.870.870.980.850.910.90.030.07
0.990.990.960.840.910.920.89-0.860.98-0.930.860.860.970.980.910.95-0.130.33
0.960.951.00.690.990.930.98-0.790.96-0.820.960.960.950.930.90.95-0.180.15
-0.21-0.21-0.18-0.17-0.13-0.23-0.150.28-0.220.09-0.16-0.16-0.06-0.20.03-0.13-0.18-0.18
0.380.410.170.630.030.46-0.01-0.50.4-0.44-0.05-0.050.210.450.070.330.15-0.18
Click cells to compare fundamentals

CRISPR Therapeutics Account Relationship Matchups

CRISPR Therapeutics Investors Sentiment

The influence of CRISPR Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in CRISPR. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to CRISPR Therapeutics' public news can be used to forecast risks associated with investment in CRISPR. The trend in average sentiment can be used to explain how an investor holding CRISPR can time the market purely based on public headlines and social activities around CRISPR Therapeutics AG. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
CRISPR Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for CRISPR Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average CRISPR Therapeutics' news discussions. The higher the estimate score, the more favorable is the investor's outlook on CRISPR Therapeutics.

CRISPR Therapeutics Implied Volatility

    
  120.16  
CRISPR Therapeutics' implied volatility exposes the market's sentiment of CRISPR Therapeutics AG stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if CRISPR Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that CRISPR Therapeutics stock will not fluctuate a lot when CRISPR Therapeutics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CRISPR Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CRISPR Therapeutics' short interest history, or implied volatility extrapolated from CRISPR Therapeutics options trading.

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with CRISPR Therapeutics

0.63CVMCel-Sci Corp Fiscal Year End 28th of December 2022 PairCorr

Moving against CRISPR Therapeutics

0.87INMInmed Pharmaceuticals Fiscal Year End 23rd of September 2022 PairCorr
0.73KZIAKazia Therapeutics Fiscal Year End 6th of October 2022 PairCorr
0.69CASICasi Pharmaceuticals Earnings Call  TodayPairCorr
0.67INVAInnoviva Normal TradingPairCorr
The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.